Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2009 1
2010 1
2011 1
2012 1
2013 5
2014 3
2015 2
2016 2
2017 2
2018 1
2019 1
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Epha3 acts as proangiogenic factor in multiple myeloma.
Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D. Caivano A, et al. Among authors: berardi s. Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100. Oncotarget. 2017. PMID: 28415715 Free PMC article.
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.
Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Mey U, Blum S, Rauch D, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Li Q, Feller A, Stussi G. Benz R, et al. Among authors: berardi s. Blood Adv. 2020 Aug 11;4(15):3699-3707. doi: 10.1182/bloodadvances.2020002160. Blood Adv. 2020. PMID: 32777066 Free PMC article. Clinical Trial.
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.
Rentsch CA, Bosshard P, Mayor G, Rieken M, Püschel H, Wirth G, Cathomas R, Parzmair GP, Grode L, Eisele B, Sharma H, Gupta M, Gairola S, Shaligram U, Goldenberger D, Spertini F, Audran R, Enoiu M, Berardi S, Hayoz S, Wicki A. Rentsch CA, et al. Among authors: berardi s. Oncoimmunology. 2020 Apr 21;9(1):1748981. doi: 10.1080/2162402X.2020.1748981. eCollection 2020. Oncoimmunology. 2020. PMID: 32363120 Free PMC article. Clinical Trial.
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R. Wicki A, et al. Among authors: berardi s. Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13. Eur J Cancer. 2018. PMID: 29660598 Clinical Trial.
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores.
Gargiulo P, Dietrich D, Herrmann R, Bodoky G, Ruhstaller T, Scheithauer W, Glimelius B, Berardi S, Pignata S, Brauchli P. Gargiulo P, et al. Among authors: berardi s. Ther Adv Med Oncol. 2019 Jan 2;11:1758835918818351. doi: 10.1177/1758835918818351. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 30636977 Free PMC article.
21 results